This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (13)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Multiple Sclerosis/ Demyelinating Disease  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Moad K. Sharief, MD, PhD; Yemane K. Semra, PhD

Arch Neurol. 2002;59:1115-1121.

Background  Treatment with interferon beta reduces clinical exacerbations in multiple sclerosis (MS) through several immunomodulatory mechanisms that involve the augmentation of programmed cell death (apoptosis) of peripheral T lymphocytes. The expression of survivin, a cell cycle–regulated antiapoptosis protein, is up-regulated in mitogen-stimulated T lymphocytes from patients with MS, and this expression correlates with MS disease activity.

Objective  To evaluate the effect of interferon beta on the expression of survivin and other apoptosis regulatory molecules in peripheral T lymphocytes from patients with MS.

Patients and Methods  In a prospective, combined clinical and immunologic study, we evaluated the expression of survivin, Bcl-2 protein, and the death receptor Fas in mitogen-stimulated T lymphocytes from 26 patients with MS, before and serially after treatment with interferon beta-1a. We also investigated the long-term effects of interferon beta-1a on cellular expression of these proteins and T-lymphocyte apoptosis in a cross-sectional study of 19 patients with MS receiving long-term interferon beta-1a therapy.

Results  Treatment with interferon beta-1a reduced the expression of survivin in in vitro stimulated T lymphocytes. This reduced expression correlated with augmented T-cell susceptibility to apoptosis and with clinical response to treatment. In contrast, interferon beta-1a therapy did not significantly alter cellular expression of Bcl-2 protein or Fas. This down-regulatory effect of interferon beta-1a on cellular expression of survivin was maintained after long-term therapy.

Conclusions  Our observations suggest that interferon beta exerts a regulatory effect on peripheral T lymphocytes through an antiapoptosis mechanism that involves the down-regulation of cellular survivin expression.

From the Department of Neuroimmunology, Guy's, King's, and St Thomas' School of Medicine, Guy's Hospital, London, England.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

X-linked Inhibitor of Apoptosis Regulates T Cell Effector Function
Zehntner et al.
J. Immunol. 2007;179:7553-7560.
ABSTRACT | FULL TEXT  

Degradation of Survivin by the X-linked Inhibitor of Apoptosis (XIAP)-XAF1 Complex
Arora et al.
J. Biol. Chem. 2007;282:26202-26209.
ABSTRACT | FULL TEXT  

Genome-Wide Network Analysis Reveals the Global Properties of IFN-beta Immediate Transcriptional Effects in Humans
Fernald et al.
J. Immunol. 2007;178:5076-5085.
ABSTRACT | FULL TEXT  

Role of the SurvivinGene in Pathophysiology
Li and Brattain
Am. J. Pathol. 2006;169:1-11.
ABSTRACT | FULL TEXT